Table 2.
Multivariate analysis of the effect of talimogene laherparepvec on overall survival.
| Covariatea | HR (95% CI) | p value |
|---|---|---|
| Sex | ||
| Female vs male | 0.40 (0.18–0.89) | .025 |
| ECOG PS | ||
| 0 vs 1 | 0.27 (0.14–0.53) | < .001 |
| Disease stage | ||
| IIIC vs IIIB | 0.15 (0.04–0.55) | < .001 |
| IV M1a vs IIIB | 0.91 (0.35–2.41) | |
| IV M1b vs IIIB | 2.07 (0.83–5.19) | |
| IV M1c vs IIIB | 1.05 (0.39–2.87) | |
| Treatment | ||
| Talimogene laherparepvec vs GM‐CSF | 0.38 (0.20–0.72) | .003 |
Abbreviations: HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; GM‐CSF, granulocyte‐macrophage colony‐stimulating factor.
a
Multivariate analysis includes prognostic covariates with imbalances at baseline.